Skip to main content

Protara Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 5, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 5, 2025

TARA$2.51+9.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 16. Form 10-K Summary

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Protara Therapeutics, Inc.
Date: March 5, 2025/s/ JESSE SHEFFERMAN
Jesse Shefferman President and Chief Executive Officer (on behalf of the registrant and as the registrant’s Principal Executive Officer)
Date: March 5, 2025/s/ PATRICK FABBIO
Patrick Fabbio Chief Financial Officer (on behalf of the registrant and as the registrant’s Principal Financial Officer)

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Jesse Shefferman and Patrick Fabbio his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ JESSE SHEFFERMANPresident and Chief Executive Officer and DirectorMarch 5, 2025
Jesse Shefferman(Principal Executive Officer)
/s/ PATRICK FABBIOChief Financial OfficerMarch 5, 2025
Patrick Fabbio(Principal Financial Officer)
/s/ HANNAH FRYVice President, ControllerMarch 5, 2025
Hannah Fry(Principal Accounting Officer)
/s/ LUKE BESHARChairman of the Board of DirectorsMarch 5, 2025
Luke Beshar
/s/ BARRY FLANNELLY, PHARM.D.DirectorMarch 5, 2025
Barry Flannelly, Pharm.D.
/s/ ROGER GARCEAU, M.D.DirectorMarch 5, 2025
Roger Garceau, M.D.
/s/ JANE HUANG, M.D.DirectorMarch 5, 2025
Jane Huang, M.D.
/s/ RICHARD LEVY, M.D.DirectorMarch 5, 2025
Richard Levy, M.D.
/s/ GREGORY P. SARGENDirectorMarch 5, 2025
Gregory P. Sargen
/s/ CYNTHIA SMITHDirectorMarch 5, 2025
Cynthia Smith
/s/ MICHAEL SOLOMON, PH.D.DirectorMarch 5, 2025
Michael Solomon, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.